Literature DB >> 31663049

Burkholderia cepacia as a cause of pyogenic spondylodiscitis in immunocompetent patients: a single-institution case series and literature review.

Maarouf Hammoud1, Youssef Fares2, Roula Atoui3, Baraa Dabboucy4.   

Abstract

Burkholderia cepacia is an important pathogen of humans in both immunocompromised and hospitalized patients. This uncommon pathogen is established to be the cause of pyogenic spondylodiscitis in only seven cases in the medical literature. Here, we report the cases of four patients who were diagnosed over two years period with Burkholderia cepacia spondylodiscitis and were successfully managed by appropriate antimicrobial treatment after open surgical biopsy was done for debridement and microbiological identification. 2019 Journal of Spine Surgery. All rights reserved.

Entities:  

Keywords:  Burkholderia cepacia; Spondylodiscitis; osteomyelitis; pyogenic

Year:  2019        PMID： 31663049      PMCID： PMC6787361          DOI： 10.21037/jss.2019.07.02

Source DB:  PubMed          Journal:  J Spine Surg        ISSN： 2414-4630


  17 in total

1.  Clinical characteristics, treatments, and outcomes of hematogenous pyogenic vertebral osteomyelitis, 12-year experience from a tertiary hospital in central Taiwan.

Authors:  Wei-Shuo Chang; Mao-Wang Ho; Po-Chang Lin; Cheng-Mao Ho; Chia-Hui Chou; Min-Chi Lu; Yen-Jen Chen; Hsien-Te Chen; Jen-Hsien Wang; Chih-Yu Chi
Journal:  J Microbiol Immunol Infect       Date:  2017-08-19       Impact factor: 4.399

Review 2.  Pyogenic spondylodiscitis: an overview.

Authors:  G S Skaf; N T Domloj; M G Fehlings; C H Bouclaous; A S Sabbagh; Z A Kanafani; S S Kanj
Journal:  J Infect Public Health       Date:  2010-02-19       Impact factor: 3.718

Review 3.  Epidemiological and clinical features of pyogenic spondylodiscitis.

Authors:  M Fantoni; E M Trecarichi; B Rossi; V Mazzotta; G Di Giacomo; L A Nasto; E Di Meco; E Pola
Journal:  Eur Rev Med Pharmacol Sci       Date:  2012-04       Impact factor: 3.507

Review 4.  Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence.

Authors:  Sophia G Avgeri; Dimitrios K Matthaiou; George Dimopoulos; Alexandros P Grammatikos; Matthew E Falagas
Journal:  Int J Antimicrob Agents       Date:  2008-12-18       Impact factor: 5.283

5.  Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome.

Authors:  O C Tablan; T L Chorba; D V Schidlow; J W White; K A Hardy; P H Gilligan; W M Morgan; L A Carson; W J Martone; J M Jason
Journal:  J Pediatr       Date:  1985-09       Impact factor: 4.406

6.  Minimally invasive dorsal percutaneous spondylodesis for the treatment of adult pyogenic spondylodiscitis.

Authors:  Martin H Deininger; Miriam I Unfried; Vassilios I Vougioukas; Ulrich Hubbe
Journal:  Acta Neurochir (Wien)       Date:  2009-05-26       Impact factor: 2.216

7.  Lumbar Spondylodiscitis Caused by Burkholderia cepacia in a Previously Healthy Patient.

Authors:  Danielle Jaafar; Maroun Rizkallah; Firas Atallah; Falah Bachour; Angelique Barakat; Ghassan Maalouf; Matta Matta
Journal:  Case Rep Orthop       Date:  2017-10-15

Review 8.  Management of spinal infection: a review of the literature.

Authors:  Sara Lener; Sebastian Hartmann; Giuseppe M V Barbagallo; Francesco Certo; Claudius Thomé; Anja Tschugg
Journal:  Acta Neurochir (Wien)       Date:  2018-01-22       Impact factor: 2.216

9.  Risk Factors and Prevention of Surgical Site Infections Following Spinal Procedures.

Authors:  Rani Nasser; Jennifer A Kosty; Sanjit Shah; Jeffrey Wang; Joseph Cheng
Journal:  Global Spine J       Date:  2018-12-13

10.  Effect of intrawound vancomycin application in spinal surgery on the incidence of surgical site infection: a meta-analysis.

Authors:  Abuduwufuer Tailaiti; Jun Shang; Shuo Shan; Aikeremujiang Muheremu
Journal:  Ther Clin Risk Manag       Date:  2018-10-31       Impact factor: 2.423
View more
  2 in total

1.  Burkholderia cepacia Complex Lumbar Spondylodiscitis: A Rare Nosocomial Infection.

Authors:  Rachel Subramanian; Lynn Fitzgibbons
Journal:  Case Rep Infect Dis       Date:  2022-02-16

2.  Talaromyces marneffei and Burkholderia cepacia Co-Infection in a HIV-Uninfected Patient with Anti-Interferon-γ Autoantibodies.

Authors:  Wen Zeng; Ye Qiu; Mengxin Tang; Hui Zhang; Mianluan Pan; Shudan Tang; Jianquan Zhang
Journal:  Infect Drug Resist       Date:  2021-06-10       Impact factor: 4.003
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.